JP2021525519A5 - - Google Patents

Info

Publication number
JP2021525519A5
JP2021525519A5 JP2020566666A JP2020566666A JP2021525519A5 JP 2021525519 A5 JP2021525519 A5 JP 2021525519A5 JP 2020566666 A JP2020566666 A JP 2020566666A JP 2020566666 A JP2020566666 A JP 2020566666A JP 2021525519 A5 JP2021525519 A5 JP 2021525519A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
nucleic acid
method characterized
antigen receptor
chimeric antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020566666A
Other languages
English (en)
Japanese (ja)
Other versions
JP7411578B2 (ja
JP2021525519A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/034900 external-priority patent/WO2019232370A1/en
Publication of JP2021525519A publication Critical patent/JP2021525519A/ja
Publication of JP2021525519A5 publication Critical patent/JP2021525519A5/ja
Application granted granted Critical
Publication of JP7411578B2 publication Critical patent/JP7411578B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020566666A 2018-06-01 2019-05-31 癌を治療するための物質及び方法 Active JP7411578B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862679348P 2018-06-01 2018-06-01
US62/679,348 2018-06-01
US201862753485P 2018-10-31 2018-10-31
US62/753,485 2018-10-31
PCT/US2019/034900 WO2019232370A1 (en) 2018-06-01 2019-05-31 Materials and methods for treating cancer

Publications (3)

Publication Number Publication Date
JP2021525519A JP2021525519A (ja) 2021-09-27
JP2021525519A5 true JP2021525519A5 (cg-RX-API-DMAC7.html) 2022-06-02
JP7411578B2 JP7411578B2 (ja) 2024-01-11

Family

ID=68698433

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020566666A Active JP7411578B2 (ja) 2018-06-01 2019-05-31 癌を治療するための物質及び方法

Country Status (11)

Country Link
US (1) US20210214723A1 (cg-RX-API-DMAC7.html)
EP (1) EP3801563B1 (cg-RX-API-DMAC7.html)
JP (1) JP7411578B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210020946A (cg-RX-API-DMAC7.html)
CN (1) CN112512533A (cg-RX-API-DMAC7.html)
AU (1) AU2019277660A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020024601A2 (cg-RX-API-DMAC7.html)
CA (1) CA3101991A1 (cg-RX-API-DMAC7.html)
ES (1) ES2959645T3 (cg-RX-API-DMAC7.html)
MX (1) MX2020013017A (cg-RX-API-DMAC7.html)
WO (1) WO2019232370A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
CN111757744A (zh) 2017-10-02 2020-10-09 人源股份有限公司 使用gm-csf拮抗剂治疗免疫疗法相关毒性的方法
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
EP3849572A4 (en) * 2018-09-10 2022-07-13 Humanigen, Inc. METHOD OF TREATMENT OF IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST
US12624086B2 (en) * 2018-10-31 2026-05-12 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
US12264189B2 (en) 2018-10-31 2025-04-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US12257286B2 (en) 2018-10-31 2025-03-25 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN113088540B (zh) * 2020-01-08 2024-12-06 上海交通大学医学院附属瑞金医院 一种gm-csf敲低的t细胞及其用途
AU2021347320A1 (en) * 2020-09-24 2023-05-11 The Jackson Laboratory Humanized mouse models for assessing immune cell therapy
CN114934071B (zh) * 2021-04-30 2023-10-17 四川大学华西医院 一种表达免疫调节因子的car载体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
PL4019041T3 (pl) 2012-07-13 2023-05-08 The Trustees Of The University Of Pennsylvania Kontrola toksyczności wobec aktywności przeciwnowotworowej CAR
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
WO2015066262A1 (en) 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
EP3359650A4 (en) * 2015-10-08 2019-03-20 Innovative Cellular Therapeutics Co., Ltd. ACTIVATION AND EXPANSION OF CELLS
EP3452499A2 (en) * 2016-05-06 2019-03-13 Juno Therapeutics, Inc. Genetically engineered cells and methods of making the same
CN107746831B (zh) * 2017-11-07 2019-04-23 南京北恒生物科技有限公司 具有化疗药物抗性的通用型cart/tcrt细胞及其构建方法

Similar Documents

Publication Publication Date Title
Li et al. Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy
EP3215605B1 (en) Improved method for the generation of genetically modified cells
JP7411578B2 (ja) 癌を治療するための物質及び方法
FI3599251T3 (fi) Cd20-antigeeniin kohdentuvan kimeerisen antigeenireseptorin rakentaminen ja sillä muunnettujen t-solujen aktiivisuuden tunnistaminen
JP2019523001A5 (cg-RX-API-DMAC7.html)
CN111051502A (zh) 通用型嵌合抗原受体t细胞制备技术
JP2025023916A5 (cg-RX-API-DMAC7.html)
Bascuas et al. Salmonella immunotherapy improves the outcome of CHOP chemotherapy in non-Hodgkin lymphoma-bearing mice
JP2022511735A5 (cg-RX-API-DMAC7.html)
JP2022517461A5 (cg-RX-API-DMAC7.html)
EA017613B1 (ru) Универсальная вакцина из опухолевых клеток для противораковой терапии и профилактического использования
Tan et al. Interferon-γ-Inducing Factor Elicits Antitumor Immunity Association with Interferon-γ Production
TW202325320A (zh) 用於產生原代免疫細胞之方法
US11098283B2 (en) T cells modified to overexpress c-Myb
Notario et al. CD69 targeting enhances anti-vaccinia virus immunity
US20190062409A1 (en) Use of modified hiv-1 for generating fully human antibodies
CN112300997A (zh) 通用型car-t细胞及其制备和应用
CN112262212B (zh) 使用羟基柠檬酸和/或其盐产生t细胞群体的方法
Jeger-Madiot et al. Germinal centers B-cell reaction and T follicular helper cells in response to HIV-1 infection
KR20250017213A (ko) 폴리뉴클레오티드
JP2022502066A5 (cg-RX-API-DMAC7.html)
EP4423145A1 (en) Methods for culturing cells expressing ror1-binding protein
US20200255802A1 (en) Method for producing b cell population
KR20200135760A (ko) Ssea4에 결합하는 키메라 항원 수용체 및 이의 용도
JP2023509849A5 (cg-RX-API-DMAC7.html)